Benoît De Renzis

Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial

Thorsten Braun, Raphaël Itzykson, Aline Renneville et al. · Blood · 2011 · 198 citations · Full text

Medicine, Oncology, Pharmacology +12

Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion

Andréa Toma, Olivier Kosmider, Sylvie Chevret et al. · Leukemia · 2015 · 121 citations · Full text

Medicine, Hematology, Pharmacotherapy +9

Efficacy and safety of pegylated‐interferon α‐2a in myelofibrosis: a study by the <scp>FIM</scp> and <scp>GEM</scp> French cooperative groups

Jean‐Christophe Ianotto, Françoise Boyer‐Perrard, Emmanuel Gyan et al. · British Journal of Haematology · 2013 · 78 citations · Full text

Medicine, Hematology, Internal Medicine +14

Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study

Jean‐Christophe Ianotto, Aurélie Chauveau, Françoise Boyer‐Perrard et al. · Haematologica · 2017 · 66 citations · Full text

Medicine, Hematology, Oncology +17

Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): A report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM)

Cécile Bally, Sylvain Thépot, Bruno Quesnel et al. · Leukemia Research · 2013 · 49 citations

Medicine, Oncology, Pharmacology +13